



July 28, 2023

**BSE Limited**

Department of Corporate Services,  
P. J. Towers,  
Dalal Street,  
**MUMBAI - 400 001.**

✓ **National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**Mumbai - 400 051.**

*Dear Sir/Madam,*

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) 2015 ('Listing Regulations').**

We are pleased to enclose a Press Note regarding Lupin Human Welfare & Research Foundation, the CSR arm of the Company, having strengthened its Desh Bandhu Jan Aarogya Sewa by flagging off its Mobile Medical Van in Jaipur.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM  
COMPANY SECRETARY  
(ACS - 11973)**

**Encl: a/a**

## Press Note

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

## Lupin Foundation Strengthens Lives Program With Its First Mobile Medical Van; Flag-Off by Health Minister, Government Of Rajasthan

*Mobile medical vans will be used to conduct 18 health camps twice a month at nine health facilities*

**Jaipur, July 28, 2023:** Lupin Human Welfare & Research Foundation (LHWRF) strengthened its Desh Bandhu Jan Aarogya Sewa by flagging off its Mobile Medical Van (MMV) in Jaipur. The fully equipped MMV was flagged off by Hon. Shri Parsadi Lal Meena, Health Minister, Government of Rajasthan, Ms. Shrubhra Singh, Additional Chief Secretary, Govt. of Rajasthan and Dr. Jitendra Soni, Mission Director, National Health Mission, Rajasthan. Dr. R.P. Mathur, Director (Public Health), Dr. Lokesh Chaturvedi Director (Reproductive & Child Health), Dr. R. N. Meena, Joint Director and State Nodal Officer (Non-Communicable Diseases) from Department of Health & Family Welfare, Rajasthan were present along with Dr. Nachiket Sule, Head-Lives Program, Mr. Ved Sharma, State Head-Rajasthan, LHWRF and Mr. Ravi Dadhich, District Program Manager, LHWRF.

The Desh Bandhu Jan Aarogya Sewa aims to enhance the well-being of communities by working towards addressing non-communicable diseases (NCDs) with high disease burden, with a specific focus on Cardiovascular and Respiratory diseases. Aligned with this goal, in November 2022, LHWRF entered a Memorandum of Understanding (MoU) with the Government of Rajasthan, forging a partnership to work together on this important area with the State Department of Health and Family Welfare.

The fully equipped MMV will function as a mobile healthcare unit, equipped to deliver a comprehensive range of essential diagnostic services and medical support. This MMV enhances access to screening, diagnostic, treatment, and disease management capabilities in the Rajgarh, Laxmangad, Renni and Kherali blocks of Alwar. Moreover, as an integral part of the initiative, 18 health camps will be conducted twice a month at nine selected health facilities. These camps will be staffed by trained MBBS doctors who will be supported by dedicated paramedical personnel.

*"We have witnessed a notable increase in cases of CVD and COPD in the region. To tackle these diseases effectively, we partnered with LHWRF, and we are confident of their ability to contribute significantly to the enhancement of specific healthcare services in the identified blocks of the Alwar district. The Mobile Medical Vans will help in bringing advanced healthcare capabilities to enhance patient health outcomes,"* said **Shri Prasadi Lal Meena, Hon. Health Minister, Government of Rajasthan.**

Speaking on the occasion, **Tushara Shankar, Head – CSR, Lupin,** said, *"Our primary objective is to enhance healthcare services related to CVD and COPD in a phased manner, specifically targeting multiple blocks within the Alwar district. By adopting a systematic approach, we aim to address these challenges by tailoring interventions and allocating resources accordingly. Our collaboration with the State Government holds immense potential for improving health outcomes and alleviating the burden associated with these two major diseases."*

## Press Note

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Non-Communicable Diseases in India account for nearly 60% of all deaths in the country. Cardiovascular disease and COPD are the two leading causes. Specifically, Rajasthan has a higher prevalence rate of cardiovascular disease and deaths due to COPD compared to the national average. The Desh Bandhu Jan Arogya Sewa focuses on respiratory and heart ailments and aims to strengthen existing primary healthcare services, working closely with government efforts. With a particular emphasis on hypertension, ischemic heart disease (IHD), cardiovascular diseases (CVD), chronic obstructive pulmonary disease (COPD), and asthma, the program seeks to provide comprehensive support to the population at risk of developing or living with these conditions.

### **About LHWRF**

Lupin Human Welfare & Research Foundation (LHWRF) is the social responsibility arm of Lupin limited, which has been working to positively impact rural landscapes since 1988. During its three-decade history, the foundation has touched over 5000 villages in 23 districts across nine states. The organization has been working to address all aspects of development for underprivileged communities in four thematic areas, namely Economic, Social, Infrastructure Development, and Natural Resource Management. It undertakes economic development activities in the fields of agriculture, animal husbandry, women empowerment, and rural industries. The social anchors include health and education, while infrastructure development and natural resource development have been the key drivers of growth in backward regions where it operates. LHWRF has adopted a new strategic approach to working on Lives (Healthcare) and Livelihoods.

### **About Lupin**

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit [www.lupin.com](http://www.lupin.com) for more information.

**For further information or queries please contact:**

**Shweta Munjal**

**Press Note**

BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

Vice President & Global Head – Corporate Communications  
Email: [shwetamunjaj@lupin.com](mailto:shwetamunjaj@lupin.com)